![]() Identification of the breast cancer susceptibility gene BRCA2. ![]() Wooster R, Bignell G, Lancaster J, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Miki Y, Swensen J, Shattuck-Eidens D, et al. The use of thresholds excluded from analysis the majority of patients carrying an UV. The Myriad II scores provided no additional information than the BRCAPRO scores alone for the detection of patients with a mutation. ![]() BRCAPRO performs better for the detection of BRCA1 mutations than of BRCA2 mutations. In summary, BRCAPRO and Myriad II are more efficient than cancer history alone to exclude patients without a mutation. Compared to cancer history, a threshold > or = 10% with BRCAPRO or with Myriad II excluded about 40% of the patients from analysis, including four with a mutation and probabilities 20% with BRCAPRO and Myriad II. DNA-analysis identified 52 mutations (16.9%) and 11 unclassified variants (UVs, 3.6%). In order to assess the added value of mutation probability methods, we have retrospectively calculated the BRCAPRO and Myriad II probabilities in 306 probands who had previously been selected for DNA-analysis according to criteria based on familial history of cancer. Considerable differences exist amongst countries in the mutation probability methods and thresholds used to select patients for BRCA1/2 genetic screening.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |